328
Participants
Start Date
August 31, 2012
Primary Completion Date
August 31, 2013
Study Completion Date
August 31, 2013
Experimental: CD07223 1.5 % Topical Gel BID
Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
Experimental: CD07223 1.5% Topical Gel TID
Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
Placebo Comparator: CD07223 vehicle gel BID
Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
Placebo Comparator: CD07223 vehicle gel TID
Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
Newtown Clinical Research, Johannesburg
Langeberg Clinical Trials, Kraaifontein
Synopsis Research, Rondebosch
Welkom Clinical Trial Center, Welkom
Cheraw Pediatrics, P.A., Cheraw
Eastern Research, Inc, Hialeah
Skin Care research Inc, Boca Raton
Integrity Clinical Research, Inc, Milan
Sealy Urgent Care Center, Sealy
SRCR, Inc, Bell Gardens
Cyn3rgy Research, Gresham
Phelang Research Center, Pretoria
Setshaba Research Center, Soshanguve
Lead Sponsor
NovaBay Pharmaceuticals, Inc.
INDUSTRY